Researchers Used Komodo’s Healthcare Map to Uncover Insights Across Oncology, Women’s Health, Mental Health, Neurology, and more
Komodo Insights Power Three Studies Named Finalists for ISPOR 2024 Research Presentation Awards
SAN FRANCISCO & ATLANTA–(BUSINESS WIRE)–Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform. The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
“We are proud to provide the data, technology foundation and services for researchers to identify gaps in care, understand risks, and ultimately, get crucial treatments to the patients who need them.”
Researchers from top institutions and Life Sciences companies leveraged Komodo’s technology platform and Healthcare Map to reveal insights focused on patterns in clinical outcomes, healthcare resource utilization (HCRU), disease burden, comparative effectiveness, and potential complications associated with approved treatments for specific patient populations.
For example, Takeda Pharmaceuticals used Komodo’s Healthcare Map in a real-world analysis of clinical outcomes and HCRU burden of people with Lennox-Gastaut syndrome (LGS), a rare type of epilepsy. Additionally, argenx and ZS Associates researchers evaluated treatment patterns in U.S. patients with chronic inflammatory demyelinating polyneuropathy and found a high treatment burden and potential unmet need with current standard of care.
“Medical breakthroughs and public health efforts are too often held back by slow data analytics workflows, but these studies exemplify the opportunity to accelerate essential insights through data and technology innovation,” said Usha Periyanayagam, MD, MPH, Head of Research and Analytics at Komodo Health. “We are proud to provide the data, technology foundation and services for researchers to identify gaps in care, understand risks, and ultimately, get crucial treatments to the patients who need them.”
Select key presentations at ISPOR 2024 include:
Oncology:
- Merck and Target RWE studied the processes and challenges of combining real-world data (RWD) for non-muscle invasive bladder cancer.
- NeoGenomics and Komodo validated an existing machine learning algorithm — built on a highly nuanced combination of data — to identify HR+/HER2- metastatic breast cancer patients, the most common breast cancer subtype.
- Komodo Health researchers used advanced AI and software tools to analyze linked RWD to investigate differences in outcomes between patients treated with CAR-T therapy and those treated with standard chemotherapy.
- Evernorth Research Institute studied the association between colorectal cancer (CRC) screening and the prevalence of advanced-stage CRC and total cost of care among U.S. adults.
Women’s Health:
- Myriad Genetics linked its proprietary data to closed claims in Komodo’s Healthcare Map to validate the accuracy of gestational age recorded using diagnostic codes. This is essential for accurate categorization of pregnancy outcomes such as miscarriage and stillbirth.
- Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
- Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.
Mental Health:
- University of Washington researchers found that antipsychotic drug shortages were associated with significant changes in utilization and even discontinuation of therapy for patients with schizophrenia and other serious mental health disorders.
- Komodo Health researchers compared therapy adherence by race and ethnicity among schizophrenia populations.
Komodo Study Recognized as a 2024 ISPOR Research Presentation Award Finalist
In an analysis that was recognized among the top 5% of studies at ISPOR this year, Komodo Health researchers examined the impact of the Clozapine Risk Evaluation and Mitigation Strategy (REMS), an FDA-mandated safety initiative, on the occurrence of neutropenia outcomes among clozapine users since the program update in 2019. By linking data from Komodo’s Healthcare Map with lab insights from Komodo’s MapEnhance solution, the analysis showed an increase in mild neutropenia following the implementation of the updated REMS policy. The study authors hypothesized that this may reflect an increase in early detection, a positive impact of the REMS program, though more research is needed.
“The growing body of research being conducted using Komodo’s platform signals an increasing demand for higher data quality and easy-to-use technology solutions that complement the insights workflow,” said Web Sun, Co-founder and President of Komodo Health. “The findings presented at ISPOR underscore the industry’s appetite for an easier way to uncover and share insights into disease trends, treatment pathways, patient populations, and a host of other complex research questions — all powered by a unified platform that can be leveraged enterprise-wide.”
For the full list of ISPOR presentations that use Komodo’s platform, click here.
About Komodo Health
Komodo Health is a technology platform company creating the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with enterprise software and machine learning that connects the dots between individual patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo helps its customers unearth patient-centric insights at scale — marrying clinical data with advanced algorithms and AI-powered software solutions to inform decision-making, close gaps in care, address disease burden, and help enterprises create a more cost-effective, value-driven healthcare system. For more information, visit Komodohealth.com.